FDA 483 - Bora Pharmaceuticals Injectables Inc - August 26, 2014
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Cangene bioPharma, Inc. dba Emergent BioSolutions in Baltimore, MD, revealed significant deficiencies in manufacturing process controls and raw material testing. The firm failed to adequately validate the scale-up of a contract drug product's formulation and filling process, neglecting to review critical analytical data. Additionally, the company accepted supplier analyses for raw materials without performing identity testing or verifying supplier reliability, raising concerns about product quality and safety.
ID · 7700f152-efc1-48b2-9523-7c6ce5bf325f